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ketones and precursors from chemical subgroup 4.1 of FGE.19: Lactones
1
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2, 3
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ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of 12 flavouring substances from subgroup 4.1 of 
FGE.19 in the Flavouring Group Evaluation 217 (FGE.217). In FGE.217, 6-methylcoumarin [FL-no: 13.012] 
was not considered genotoxic and was therefore evaluated through the Procedure in FGE.80Rev1. For the 
remaining 11 substances, the Panel concluded that based on the data available, a genotoxic potential could not 
be excluded and accordingly they could not be evaluated through the Procedure. Additional data on genotoxicity 
for the three representative substances, 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023], 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 10.066], have now been 
provided. Based on the new data, the Panel concluded that 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 
10.023] does not give rise to concern with respect to genotoxicity  and can accordingly,  together with the 
structurally related substance, 3-hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030] for which it is a 
representative,  be evaluated using the Procedure. For 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 
10.042]  and furan-2(5H)-one [FL-no: 10.066] the concern for genotoxicity could not be ruled out and a 
combined micronucleus and Comet assay is requested for these two substances, covering the remaining seven 
substances [FL-no: 10.034, 10.036, 10.043, 10.046, 10.054, 10.057 and 10.060]. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids  (CEF Panel) was asked to deliver a scientific  opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate 12 flavouring substances in 
Flavouring Group Evaluation 217 (FGE.217) using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000.  
The FGE.217 concerned 12 substances, corresponding to subgroup 4.1 of FGE.19. The 12 substances 
are α,β-unsaturated lactones [FL-no: 10.023, 10.030, 10.034, 10.036, 10.042, 10.043, 10.046, 10.054, 
10.057, 10.060, 10.066 and 13.012], which by hydrolysis and oxidation gives rise to α,β-unsaturated 
ketones, which is a structural alert for genotoxicity.  
In FGE.217, 6-methylcoumarin [FL-no: 13.012] was not considered genotoxic and was therefore 
allocated to FGE.80Rev1 for evaluation through the Procedure. For the remaining 11 substances, the 
Panel concluded that based on the data available, a genotoxic potential could not be excluded and 
accordingly they could not be evaluated through the Procedure. Additional data on genotoxicity for 
three representative substances,  5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023], 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 10.066], of this 
subgroup, should be provided. The present revision of FGE.217 (FGE.217Rev1) deals with additional 
data submitted by the Industry in response to the EFSA request expressed in FGE.217. 
In vitro  data in bacteria and mammalian test systems have now been provided for the three 
representative substances [FL-no: 10.023, 10.042 and 10.066] selected by the EFSA. 
Based on these new data the Panel concluded that the genotoxic concern could be ruled out for 5-
ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] and accordingly this substance, and the 
one structurally related substance, 3-hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030],  for 
which it is a representative, can be evaluated using the Procedure. For the two remaining 
representative substances, 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-
2(5H)-one [FL-no: 10.066], the test results from the studies in mammalian test systems raise concern 
with respect to genotoxicity in vitro and accordingly, these two substances [FL-no: 10.042 and 
10.066] and the seven substances [FL-no: 10.034, 10.036, 10.043, 10.046, 10.054, 10.057 and 10.060] 
for which these two substance were representatives cannot be evaluated using the Procedure until 
additional in vivo genotoxicity data will become available. According to the recommendations of 
EFSA Scientific Committee (EFSA, 2011) a combined micronucleus and Comet assay should be 
considered. The Comet assay should be performed at least in the liver. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000. 
EFSA has evaluated 12 flavouring substances, which correspond to subgroup 4.1 of FGE.19, in its 
evaluation of the flavouring group 217 (FGE.217). The opinion was adopted on 29 January 2009. 
EFSA concluded that a genotoxic potential of the 11 α,β-unsaturated ketones and precursors in the 
present FGE.217 could not be ruled out.  
Information on the three representative materials 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 
10.023], 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 
10.066] has now been submitted by the European Flavour Association. This information is intended to 
cover also the re-evaluation of the following eight substances from FGE.19 subgroup 4.1 (FGE.217): 
•  3-Hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030] 
•  5,6-Dihydro-3,6-dimethylbenzofuran-2(4H)-one [FL-no: 10.034] 
•  5,6,7,7a-Tetrahydro-3,6-dimethylbenzofuran-2(4H)-one [FL-no: 10.036] 
•  2,7-Dimethylocta-5(trans),7-dieno-1,4-lactone [FL-no: 10.043] 
•  Hex-2-eno-1,4-lactone [FL-no: 10.046] 
•  Non-2-eno-1,4-lactone [FL-no: 10.054] 
•  3a,4.5.7a-Tetrahydro-3,6-dimethylbenzofuran-2(3H)-one [FL-no: 10.057] 
•  2-Decen-1,4-lactone [FL-no: 10.060] 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following eleven flavouring substances: 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-
one [FL-no: 10.023],  3-hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030], 5,6-dihydro-3,6-
dimethylbenzofuran-2(4H)-one [FL-no: 10.034], 5,6,7,7a-tetrahydro-3,6-dimethylbenzofuran-2(4H)-
one [FL-no: 10.036], 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042], 2,7-dimethylocta-
5(trans),7-dieno-1,4-lactone [FL-no: 10.043], hex-2-eno-1,4-lactone [FL-no: 10.046], non-2-eno-1,4-
lactone [FL-no: 10.054], 3a,4.5.7a-tetrahydro-3,6-dimethylbenzofuran-2(3H)-one [FL-no: 10.057], 2-
decen-1,4-lactone [FL-no: 10.060]  and  furan-2(5H)-one [FL-no: 10.066] in accordance with 
Commission Regulation (EC) N° 1565/2000. Flavouring Group Evaluation 217Rev1 
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HISTORY 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999), as last amended by Commission Decision 2009/163/EC (EC, 
2009). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000), which is broadly based on the 
opinion of the Scientific Committee on Food (SCF, 1999). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002).  
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/2012 (EC, 2012). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship ((Q)SAR)  prediction of the genotoxicity of these 
substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-
MultiCASE Models and ISS-Local Models (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b)  and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. The Panel decided that 11 subgroups (1.1.2, 
1.1.3, 1.1.4, 2.4, 2.6, 2.7, 3.1, 3.3, 4.1, 4.2 and 4.4) of FGE.19 (EFSA, 2008a) should be further 
examined to determine whether evaluation through the Procedure is feasible. Corresponding to these 
11 subgroups, 11 Flavouring Group Evaluations (FGEs) were established (FGE.201, 202, 203, 210, 
212, 213, 214, 216, 217, 218 and 220). If the Panel concludes for any substances in these 11 FGEs that 
they cannot be evaluated using the Procedure, then it has to be decided if there is a safety concern for 
certain substances or if additional data are required in order to finalise the evaluation. If the Panel 
concludes that a genotoxic potential can be ruled out for the substances, they will be merged with 
structurally related substances in other FGEs and evaluated using the Procedure. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA has worked out a  list of Flavouring Group Evaluation 217Rev1 
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representative substances for each subgroup (EFSA, 2008c). Likewise, an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008b).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.  
The Flavouring Industry has now submitted additional data and the present revision of  FGE.217 
concerns the evaluation of these data requested on genotoxicity. 
PRESENTATION OF THE SUBSTANCES BELONGING TO THE FLAVOURING GROUP 
EVALUATION 217 CORRESPONDING TO FGE.19 SUBGROUP 4.1 
The Flavouring Group Evaluation 217 (FGE.217) concerns 12 substances, which are presented in 
Table 1. These 12 substances correspond to subgroup 4.1 of FGE.19 (EFSA, 2008a). All the 
substances  are  α,β-unsaturated lactones [FL-no: 10.023, 10.030, 10.034, 10.036, 10.042, 10.043, 
10.046, 10.054, 10.057, 10.060, 10.066 and 13.012], which by hydrolysis and oxidation give rise to 
alpha,beta-unsaturated ketones.  
The  α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). Accordingly, the available data on genotoxic or carcinogenic activity for the 12 lactones [FL-
no: 10.023, 10.030, 10.034, 10.036, 10.042, 10.043, 10.046, 10.054, 10.057, 10.060, 10.066 and 
13.012] in FGE.217, anticipated to be metabolised to α,β-unsaturated ketones, will be considered in 
this FGE. Flavouring Group Evaluation 217Rev1 
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SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 217REV1  
Table 1:   Specification Summary of the Substances in the present group 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
10.023 
222 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one 
 
3153 
2300 
698-10-2 
Liquid 
C7H10O3   
142.15 
Soluble 
 
83-86 (1 hPa) 
 
IR 
95 % 
1.486-1.493 
1.134-1.144 
10.030 
243 
3-Hydroxy-4,5-dimethylfuran-2(5H)-one 
 
3634 
11834 
28664-35-9 
Liquid 
C6H8O3  
128.13 
 
 
81 (8 hPa) 
25 
IR 
97.5 % 
 
 
10.034 
1163 
5,6-Dihydro-3,6-dimethylbenzofuran-2(4H)-
one 
 
3755 
 
80417-97-6 
Liquid 
C10H12O2 
164.20 
Slightly soluble 
Soluble 
264-266 (13hPa) 
 
IR NMR 
95 % 
1.542-1.548 
1.090-1.096 
10.036 
1162 
5,6,7,7a-Tetrahydro-3,6-dimethylbenzofuran-
2(4H)-one 
 
3764 
 
13341-72-5 
Liquid 
C10H14O2 
166.22 
Slightly soluble 
Soluble 
261-263 (8 hPa) 
 
IR NMR 
98 % 
1.497-1.503 
1.058-1.063 
10.042 
 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one    
 
4050 
11873 
774-64-1 
Liquid 
C11H16O2 
180 
Soluble 
Freely soluble 
303 
 
MS 
93 % 
1.560-1.575 
0.980-1.000 
10.043 
 
2,7-Dimethylocta-5(trans),7-dieno-1,4-lactone 
 
 
 
74183-60-1 
Liquid 
C10H14O2 
166.22 
Practically insoluble or 
insoluble 
Freely soluble 
132 (8 hPa) 
 
NMR 
95 % 
1.453-1.459 
0.977-0.983 
10.046 
 
Hex-2-eno-1,4-lactone 
 
 
 
2407-43-4 
Liquid 
C6H8O2 
112.13 
 
Soluble 
93 (13 hPa) 
 
 
95 % 
1.431-1.437 
1.067-1.073 
10.054 
 
Non-2-eno-1,4-lactone 
 
4188 
 
21963-26-8 
Liquid 
C9H14O2 
154.21 
Practically insoluble or 
insoluble 
Freely soluble 
196 
 
 
95 % 
1.457-1.463 
0.981-0.987 
10.057 
 
3a,4,5,7a-Tetrahydro-3,6-dimethylbenzofuran-
2(3H)-one   
4140 
 
57743-63-2 
Liquid 
C10H14O2 
166.22 
Practically insoluble or 
insoluble 
Freely soluble 
231 
13 
 
95 % 
1.494-1.500 
1.053-1.059 
O O
OH
O
O
OH
O
O
O O
O
O
O
O
O
O
O
O
O
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Table 1:   Specification Summary of the Substances in the present group 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
10.060 
 
2-Decen-1,4-lactone 
 
 
 
2518-53-8 
Liquid 
C10H16O2 
168.24 
Practically insoluble 
Freely soluble 
145 (13 hPa) 
 
MS 
95 % 
1.457-1.463 
0.976-0.981 
10.066 
 
Furan-2(5H)-one 
 
4138 
 
 
Liquid 
C4H4O2 
84.07 
Soluble 
Freely soluble 
214 
 
 
95 % 
1.457-1.463 
1.182-1.188 
13.012 
1172 
6-Methylcoumarin 
 
2699 
579 
92-48-8 
Solid 
C10H8O2 
160.17 
Insoluble 
Soluble 
 
73-79 
IR 
99 % 
n.a. 
n.a. 
1)  Solubility in water, if not otherwise stated. 
2)  Solubility in 95 % ethanol, if not otherwise stated. 
3)  At 1013.25 hPa, if not otherwise stated. 
4)  At 20°C, if not otherwise stated. 
5)  At 25°C, if not otherwise stated. 
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ASSESSMENT 
1.  History of the FGE.217 Evaluation 
In  the first scientific opinion on FGE.217  (EFSA, 2009), the Panel concluded that additional 
genotoxicity data were required for 11 of the 12 α,β-unsaturated lactones considered in the FGE. For 
one substance, 6-methylcoumarin [FL-no: 13.012], the concern for genotoxicity could be ruled out and 
accordingly the substance could be evaluated using the Procedure in FGE.80Rev1. As  6-
methylcoumarin is the only substance in FGE.217 with the α,β-ketone grouping in conjugation with 
an aromatic ring, this substance would not be considered a representative for any of the remaining α,β-
unsaturated lactones in this subgroup. 
In  the  EFSA  opinion  “List  of  α,β-unsaturated aldehydes and ketones representative of FGE.19 
substances for genotoxicity testing” (EFSA, 2008c), three representative flavouring substances have 
been selected (Table 2) for the remaining 11 substances of FGE.19, subgroup 4.1, corresponding to 
FGE.217. 5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] is a  representative  for  the 
structurally related substance 3-hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030], while 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one [FL-no 10.042]  and furan-2(5H)-one [FL-no 10.066] are 
representatives of the remaining seven substances [FL-no: 10.034, 10.036, 10.043, 10.046, 10.054, 
10.057 and 10.060]. 
 
Table 2:   Representative substances selected by EFSA for FGE.19 Subgroup 4.1 (FGE.217) 
Representative substances for subgroup 4.1b of FGE.19 (EFSA, 2008c) 
FL-no  
JECFA-no  
EU Register name   Structural formula  
10.023 
222 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one 
 
 
10.042 
- 
 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one 
 
 
10.066 
- 
Furan-2(5H)-one 
 
 
The Panel viewed the previous JEFCA evaluations (JECFA, 1998; JECFA, 2004)  (Table 3) and 
reached the conclusions based on the data available at that time. These included a (Q)SAR prediction 
analysis (Table 4), a carcinogenicity study on 6-methylcoumarin [FL-no: 13.012] (Table 5), four in 
vitro studies (Table 6) and three in vivo studies on 6-methylcoumarin [FL-no: 13.012] (Table 7). 
In Table 4 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro 
(Q)SAR models (ISS Local Model-Ames test, DTU-NFI MultiCASE-Ames test, Chromosomal 
aberration test in Chinese hamster ovary cells (CHO), Chromosomal aberration test in Chinese 
hamster lung cells (CHL) and Mouse lymphoma test) are presented. For all of the substances the 
(Q)SAR models predict negative or out of domain results for the Ames test system except for one 
positive prediction for 6-methylcoumarin [FL-no: 13.012]. For the predictions in the Mouse 
lymphoma test and the Chromosomal aberration test in CHO and CHL, the results are inhomogeneous 
(in most cases either negative, out of domain or equivocal). The only positive predictions are seen in 
the Mouse lymphoma test for the furan-2(5H)-one [FL-no: 10.066] and in the Chromosomal aberration 
test for hex-2-eno-1,4-lactone [FL-no: 10.046]. 
O O
OH
O
O
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The Carcinogenicity Study (Hagan et al., 1967) performed with 6-methylcoumarin [FL-no: 13.012] is 
reported in Table 5. Groups of 25 male and 25 female weanling Osborne-Mendel rats were fed diets 
containing 0, 500, 1000, 3500, 5000, 7500 or 15000 mg/kg body weight (bw)/day 6-methylcoumarin 
[FL-no: 13.012] for two years, corresponding to 0, 25, 50, 175, 250, 375 or 750 mg 6-
methylcoumarin/kg bw/day. The NOAEL was 250 mg/kg bw/day based on growth depression and 
slight liver changes, particularly in males at the higher dose levels. No carcinogenicity was observed 
in this study (Hagan et al., 1967). The Panel also noted that this study was performed before OECD 
test guidelines 451/453 (1981) (OECD, 2009a and OECD, 2009b) were established and that it does not 
meet the criteria of these OECD Test Guidelines with respect to the number of animals. However, the 
Panel agreed with the conclusion of the authors that 6-methylcoumarin  [FL-no: 13.012] was not 
carcinogenic in rats under the study conditions. 
Genotoxicity studies were only available for 6-methylcoumarin [FL-no: 13.012]. In the Ames studies, 
6-methylcoumarin was found negative in two valid tests (Haworth et al., 1983; Brusick, 1982), while 
results were equivocal in a valid study with strain TA100 (Wild et al., 1983) (Table 6). 6-
Methylcoumarin was found negative in a valid mouse lymphoma tk assay (Cifone, 1982) (Table 6). 
Furthermore, 6-methylcoumarin was found negative in the three in vivo studies considered of limited 
validity, a Drosophila melanogaster sex-linked recessive lethal test (Wild et al., 1983), a mouse bone 
marrow micronucleus assay (Wild et al., 1983) and a mouse peripheral blood micronucleus 90-day 
assay reported by Witt et al. (Witt et al., 2000) (Table 7).  
The Panel concluded that the data available do not indicate a genotoxic or carcinogenic potential for 6-
methylcoumarin [FL-no: 13.012]. However, 6-methylcoumarin is the only substance in FGE.217 with 
the α,β-ketone grouping in conjugation with an aromatic ring, therefore, this substance would not be 
considered a representative for the remaining α,β-unsaturated lactones in this group. 
Based on the data previously available, a genotoxic potential of the remaining 11 substances in the 
present FGE [FL-no: 10.023, 10.030, 10.034, 10.036, 10.042, 10.043, 10.046, 10.054, 10.057, 10.060 
and 10.066] could not be excluded. Therefore, the Panel concluded that additional data on 
genotoxicity for representative substances of this subgroup should be provided according to the 
Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008b). 
 
2.  Additional Genotoxicity Data Submitted for FGE 19, subgroup 4.1  
Based on Panel request described in Section 1, additional data have been provided by Industry (IOFI, 
2012a; IOFI, 2012b) for the three representative substances, 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-
one [FL-no: 10.023], dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one 
[FL-no: 10.066] (Table 2, Section 1), as requested by the EFSA. The present FGE.217, Revision 1 
(FGE.217Rev1),  includes the assessment of these additional genotoxicity data. The study types 
provided are shown below: 
 
Substance / study type  Ames test  Micronucleus assay 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023]  Bowen, 2011a  Lloyd, 2011 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042]  Bowen, 2011b  Whitwell, 2012a  
Furan-2(5H)-one [FL-no: 10.066]  Bowen, 2011c  Whitwell, 2012b 
FGE  Adopted by 
EFSA 
Link  No. of 
Substances 
FGE.217  29 January 2009  http://www.efsa.europa.eu/en/efsajournal/pub/1068.htm  12 
FGE.217Rev1  4 July 2013    12 Flavouring Group Evaluation 217Rev1 
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2.1.  In vitro data 
 
2.1.1.  Bacterial Reverse Mutation Assay 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] was tested for mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of Salmonella typhimurium, both in 
the  absence and in the presence of metabolic activation by an Aroclor 1254-induced rat liver post-
mitochondrial fraction (S9-mix), in two separate experiments. An initial toxicity range finding 
experiment was carried out in the absence and in the presence of the S9-mix in strain TA100 (Bowen, 
2011a). 
In experiment 1, treatments were performed in all tester strains in the absence and in the presence of 
S9-mix at concentrations of 1.6, 8, 40, 200, 1000 and 5000 μg/plate. Following these treatments, 
evidence of toxicity was observed in strain TA1537 in the presence of S9-mix at 5000 μg/plate and in 
strain TA102 in the presence of S9-mix at 200 μg/plate and above. Further evidence of toxicity in the 
form of a reduction in revertant numbers was observed in strain TA1535 in the presence of S9-mix 
and in strain TA102 in the absence of S9-mix at 5000 µg/plate. 
In experiment 2, treatments were performed in all the tester strains in the absence and in the presence 
of S9-mix, using more narrow concentration intervals covering the range 156.3 - 5000 μg/plate. In 
addition, all treatments in the presence of S9-mix were further modified by the inclusion of a pre-
incubation step. The maximum test concentration of 5000 μg/plate was retained for all strains. 
Following these treatments, evidence of toxicity was observed in the presence of S9-mix in strains 
TA1537 and TA102 at 2500 μg/plate and above. Further evidence of toxicity in the form of a 
reduction in revertant numbers was observed in strains TA98 in the presence of S9-mix at 5000 
µg/plate and in strains TA98 and TA102 in the absence of S9-mix at 5000 and 2500 µg/plate, 
respectively. 
No statistically significant increases in revertant numbers were observed following 5-ethyl-3-hydroxy-
4-methylfuran-2(5H)-one treatments in any of the test strains, either in the absence or presence of S9-
mix, in either experiment.  
The Panel concluded that 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] did not induce 
mutation in five histidine-requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. 
typhimurium when tested under the conditions of this study. These conditions included treatments at 
concentrations  up  to  5000  μg/plate,  in  the absence and in the presence of a rat liver metabolic 
activation system (S9-mix). 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] was tested for mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium, both in the absence 
and in the presence of metabolic activation by an Aroclor 1254-induced rat liver post-mitochondrial 
fraction (S9-mix), in two separate experiments and a third experiment performed in TA1537 (Bowen, 
2011b). 
In experiment 1, treatments were performed in all tester strains in the absence and in the presence of 
S9-mix at concentrations of 0.32, 1.6, 8, 40, 200, 1000 and 5000 μg/plate. Following these treatments 
evidence of toxicity was observed in all strains at the highest, second highest, and/or third highest 
concentrations in both the presence and absence of S9-mix metabolic activation. Flavouring Group Evaluation 217Rev1 
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In experiment 2, treatments were performed in all the tester strains in the absence and in the presence 
of S9-mix, using more narrow concentration intervals. For strains TA98, TA1535 and TA102, the 
range in both the absence and presence of S9-mix was 78.13 - 5000 μg/plate. For strain TA100 the 
concentration ranges were 78.13 - 5000 μg/plate in the presence of S9-mix and 19.53 - 1250 μg/plate 
in the absence of S9-mix. For strain TA1537 the concentration ranges were 9.76 - 1250 μg/plate in the 
absence of S9-mix and 78.13 -  5000  μg/plate  in  the  presence  of  S9-mix. In this experiment all 
treatments done in the presence of S9-mix utilised a pre-incubation step. After incubation, evidence of 
toxicity was observed for all strains at 312.5 or 625 μg/plate and higher, except for strain TA102 in the 
presence of S9-mix where the toxicity was only observed at 1250 μg/plate and above. No increases in 
revertant numbers were observed in any strains in the presence or absence of S9-mix. For strain 
TA1537, there were too few non-toxic concentrations to fully assess the mutagenic potential in the 
presence of S9-mix. Therefore, a third experiment in the presence of S9-mix was carried out using the 
pre-incubation methodology at a concentration range of 19.53 - 1250 μg/plate. Evidence of toxicity 
was  observed  at  156.3  μg/plate  and  above.  Thus,  the  study  design  complied with current 
recommendations from OECD  Test  Guideline 471  (OECD, 1997). No statistically significant 
increases in revertant numbers were observed.  
The Panel concluded that 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] did not induce 
mutation in five histidine-requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. 
typhimurium when tested under the conditions of this study. These conditions included treatments up 
to toxic concentrations, in the absence and in the presence of a rat liver metabolic activation system 
(S9-mix). 
Furan-2(5H)-one [FL-no: 10.066] 
Furan-2(5H)-one [FL-no: 10.066] was tested for mutation in five histidine-requiring strains (TA98, 
TA100, TA1535, TA1537 and TA102) of S. typhimurium, both in the absence and in the presence of 
metabolic activation by an Aroclor 1254-induced rat liver post-mitochondrial fraction (S9-mix), in two 
separate experiments (Bowen, 2011c). 
In experiment 1, treatments were performed in all tester strains in the absence and in the presence of 
S9-mix at concentrations of 0.32, 1.6, 8, 40, 200, 1000 and 5000 μg/plate. Following these treatments 
evidence of toxicity was observed in all strains at 5000 μg/plate with the exception of TA100 in the 
presence of S9-mix activation and TA1535 in the absence of S9-mix. No increases in revertant 
numbers were observed in any strains in the presence or absence of S9-mix.  
In experiment 2, treatments were performed in all the tester strains in the absence and in the presence 
of S9-mix, using a narrower concentration range of 156.3 - 5000 μg/plate. In this experiment all 
treatments done in the presence of S9-mix utilized a pre-incubation step. Evidence of toxicity was 
observed for all strains in the presence and absence of S9-mix at 2500 and/or 5000 μg/plate. Thus, the 
study design complied with current recommendations from OECD Test Guideline 471 (OECD, 1997). 
No increases in revertant numbers were observed in any strains in the presence or absence of S9-mix. 
The Panel concluded that furan-2(5H)-one [FL-no: 10.066] did not induce mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium when tested under 
the conditions of this study. These conditions included treatments up to toxic concentrations, in the 
absence and in the presence of a rat liver metabolic activation system (S9-mix). 
2.1.2.  Micronucleus Assays 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] was tested for the induction of 
chromosome damage and potential aneugenic effects in an in vitro micronucleus assay using duplicate 
human peripheral blood lymphocytes prepared from pooled blood from two healthy male volunteers in Flavouring Group Evaluation 217Rev1 
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a single experiment. Treatments were performed both in the absence and presence of Aroclor 1254 
induced rat liver S9-mix (Lloyd, 2011).  
Treatment with 5-methyl-2-thiophenecarbaldehyde was conducted 48 hours after culture initiation 
(stimulation by phytohaemagglutinin).  
 
A preliminary toxicity range finding experiment was conducted with and without S9-mix for 3 hours 
treatment and 21 hours of recovery (3 + 21 hours) and without S9-mix for 24 hours treatment. Toxicity 
was evaluated as the effect of treatment on the Replication Index (RI). Ten concentrations from 14,33 
to 1422 μg/mL were tested. The concentrations selected for the main experiments were based on 
toxicity data from this preliminary test. 
5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-one was tested (Lloyd, 2011) at concentrations 1000, 1200 
and  1422  μg/mL  (equivalent  to  10  mM),  in  the  absence  and  presence  of  S9-mix, resulted in 
frequencies of micronucleated binucleate cells (MNBN), which were similar to those observed in 
concurrent vehicle controls for all concentrations analysed, and fell within historical vehicle control 
(normal) ranges. The above treatment concentrations induced maximum cytotoxicity (reduction in 
replication index) of 10 % in the absence of S9-mix activation and 23 % in the presence of S9-mix 
activation. Thus, the study design complies with current recommendations (including OECD Test 
Guideline 487 (OECD, 2010)). No increases in MNBN cells were observed following continuous 24 
hours treatment in the absence of S9-mix at concentrations of 500, 750 and 900 µg/mL, the top 
concentration inducing 53 % cytotoxicity. These data indicated absence of induction of MNBN cells 
as a result of treatment with 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one at concentrations either 
reaching 10 mM or inducing 50 - 60 % toxicity. 
The Panel concluded that 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] does not 
induce micronuclei in cultured human peripheral blood lymphocytes following treatment in the 
absence or in the presence of S9-mix. All values were within historical vehicle control ranges in all 
parts of the study and were not significantly different from concurrent controls. 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-one  [FL-no: 10.042] was tested for the induction of 
chromosome damage and potential aneugenic effects in an in vitro micronucleus assay using duplicate 
human peripheral blood lymphocytes prepared from pooled blood from two healthy female volunteers 
in a single experiment. Treatments were performed both in the absence and presence of Aroclor 1254 
induced rat liver S9-mix (Whitwell, 2012a).  
A preliminary toxicity range finding experiment was conducted with and without S9-mix for 3 hours 
treatment followed by 21 hours recovery period and without S9-mix for 24 hours treatment. Toxicity 
was evaluated as the effect of treatment on the Replication Index (RI). Twelve concentrations from 
7.256 to 2000 μg/mL were tested. The concentrations selected for the main experiments were based on 
toxicity data from this preliminary test (Whitwell, 2012a).  
Cells were stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells, 
and then treated for 3 hours (followed by 21 hours recovery) with 0, 40, 60, 70 and 90 μg/ml of 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one in the absence of S9-mix and 0, 60, 90, 110 and 140 μg/ml in 
the presence of S9-mix. The levels of cytotoxicity (reduction in replication index) at the top 
concentrations were 57 % and 56 %, respectively. In a parallel assay, cells were treated for 24 hours 
with 0, 10, 13 and 15 μg/ml of 3,4-dimethyl-5-pentylidenefuran-2(5H)-one in the absence of S9-mix 
with no recovery period. The top concentration induced 57 % cytotoxicity. There were 2 replicate 
cultures per treatment, and 100 binucleate cells per replicate were scored for micronuclei. Thus the 
study design complies with current recommendations (OECD Test Guideline 487 (OECD, 2010)).  Flavouring Group Evaluation 217Rev1 
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Treatment of cells with 3,4-dimethyl-5-pentylidenefuran-2(5H)-one for 3 hours with a 21 hours 
recovery period showed an increase in the frequency of MNBN cells at concentration levels of 70 and 
90 μg/ml (p ≤ 0.05) in the absence of S9-mix, but these were significantly below the 95 % confidence 
interval of the normal control range (0.10 - 1.60 %) and are not considered biologically relevant by the 
applicant. In the presence of S9-mix, treatment of cells with 3,4-dimethyl-5-pentylidenefuran-2(5H)-
one for 3 + 21 hours showed an increase in the frequency of MNBN cells at concentration levels of 60 
(p ≤ 0.01), 90, 110 and 120 μg/ml (p ≤ 0.001). No significant increases in MNBN frequencies were 
observed at any concentration after treatment for 24 hours with no recovery period. It was concluded 
that 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] induced micronuclei when assayed 
in cultured human peripheral lymphocytes for 3 + 21 hours in the presence of S9-mix (Whitwell, 
2012a). 
Furan-2(5H)-one [FL-no: 10.066] 
Furan-2(5H)-one [FL-no: 10.066] was tested for the induction of chromosome damage and potential 
aneugenic effects in an in vitro micronucleus assay using duplicate human peripheral blood 
lymphocytes prepared from pooled blood from two healthy male volunteers in a single experiment. 
Treatments were performed both in the absence and presence of Aroclor 1254 induced rat liver S9-mix 
(Whitwell, 2012b).  
A preliminary toxicity range finding experiment was conducted with and without S9-mix for 3 hours 
treatment and 21 hours recovery (3 + 21 hours) and without S9-mix for 24 hours treatment. Toxicity 
was evaluated as the effect of treatment on the Replication Index (RI). Twelve concentrations from 
3.047 to 840 μg/mL were tested. The concentrations selected for the main experiments were based on 
toxicity data from this preliminary test (Whitwell, 2012b).  
Cells were stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells, 
and then treated for 3 + 21 hours with 0, 200, 350, 425, 450 and 475 μg/ml furan-2(5H)-one in the 
absence of S9-mix and 0, 100, 250, 425, 450 and 475 μg/ml in the presence of S9-mix. The levels of 
cytotoxicity (reduction in replication index) at the top concentrations were 53 and 51 % respectively. 
In a parallel assay, cells were treated for 24 hours with 0, 10, 50, 60, 67.5 and 72.5 μg/ml of furan-
2(5H)-one in the absence of S9-mix with no recovery period. The top concentration induced 61 % 
cytotoxicity. There were two replicate cultures per treatment, and 1000 binucleate cells per replicate 
were scored for micronuclei. Thus, the study design complies with current recommendations (OECD 
Test Guideline 487 (OECD, 2010)).  
Treatment of cells with furan-2(5H)-one for 3 + 21 hours showed an increase in the frequency of 
MNBN cells at a concentration of 450 μg/ml (p ≤ 0.05) in the absence of S9-mix, but it was associated 
with 64 % cytotoxicity to the cells and is not considered biologically relevant by the applicant. In the 
presence of S9-mix, treatment of cells with furan-2(5H)-one for 3 + 21 hours  showed an increase in 
the frequency of MNBN cells at the three top concentrations (p  ≤ 0.001), and all were significantly 
above the 95 % confidence interval of the normal control range (0.10 - 1.10 %). Treatment for 24 
hours with no recovery period showed an increase in MNBN frequencies at the top dose only, but it 
was lower than the 95 % confidence interval of the historical control range and it was associated with 
high cytotoxicity (61 %) by the applicant.  
The Panel concluded that furan-2(5H)-one  induces  micronuclei when assayed in cultured human 
peripheral lymphocytes for 3 + 21 hours in the presence of S9-mix (Whitwell, 2012b). 
The results of the additional in vitro studies are summarised in Table 8. 
2.2.  Additional available data 
In more recent literature, the only reference to the potential of furanone compounds to induce DNA 
damage has been reported in association with the reduction of trivalent copper in an in vitro DNA 
damage assay (Murakami et al., 2007). Of three furanone analogues tested, 2,5-furanone (furaneol, 4-Flavouring Group Evaluation 217Rev1 
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hydroxy-2,5-dimethyl-furan-3-one [FL-no: 13.010] in FGE.220), 4,5-furanone  (3-hydroxy-4,5-
dimethylfuran-2(5H)-one [FL-no: 10.030]) and cyclotene (2-hydroxy-3-methyl-2-cyclopenten-1-one 
[07.056] in FGE.213 – not a furanone), only the first produced 8-hydroxy-2'-deoxyguanosine in DNA 
and strand breaks. These were associated with the generation of reactive oxygen species (superoxide 
radical) through the reduction of trivalent cupric to divalent cuprous ions. In contrast, to 2,5-furanone, 
the 4,5-analogue [FL-no: 10.030], which is one of the 12 substances evaluated in this group, did not 
produce a similar effect. These observations indicate that genotoxicity associated with members of the 
nine substances in group 4.1 is likely to be indirect and mediated via oxidative stress. 
3.  Conclusion 
The FGE.217 concerned 12 substances, corresponding to subgroup 4.1 of FGE.19. The 12 substances 
are α,β-unsaturated lactones [FL-no: 10.023, 10.030, 10.034, 10.036, 10.042, 10.043, 10.046, 10.054, 
10.057, 10.060, 10.066 and 13.012], which by hydrolysis and oxidation gives rise to α,β-unsaturated 
ketones, which is a structural alert for genotoxicity.  
In FGE.217, 6-methylcoumarin [FL-no: 13.012] was not considered genotoxic and was therefore 
allocated to FGE.80Rev1 for evaluation through the Procedure. For the remaining 11 substances, the 
Panel concluded that based on the data available, a genotoxic potential could not be excluded and 
accordingly they could not be evaluated through the Procedure. Additional data on genotoxicity for 
three representative substances,  5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023], 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 10.066], of this 
subgroup, should be provided according to the Genotoxicity Test Strategy for Substances Belonging to 
Subgroups of FGE.19. The present revision of FGE.217 (FGE.217Rev1) deals with additional data 
submitted by the Industry in response to the EFSA request expressed in FGE.217. 
In  vitro  data in bacteria and mammalian test systems have now been provided for the three 
representative substances [FL-no: 10.023, 10.042 and 10.066] selected by the EFSA. 
The three representative substances 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023], 3,4-
dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 10.066] did not 
induce mutations in bacterial reverse mutation assays. In an in vitro micronucleus (MNvit) assay, 5-
ethyl-3-hydroxy-4-methylfuran-2(5H)-one [FL-no: 10.023] also did not reveal genotoxic effects under 
all test conditions according to OECD Test Guideline 487  (OECD, 2010). The Panel therefore 
concluded that the genotoxic concern could be ruled out for 5-ethyl-3-hydroxy-4-methylfuran-2(5H)-
one [FL-no: 10.023] and accordingly this substance and the one structurally related substance, 3-
hydroxy-4,5-dimethylfuran-2(5H)-one [FL-no: 10.030] for which it is a representative, can be 
evaluated using the Procedure. 
In the in vitro micronucleus assay 3,4-dimethyl-5-pentylidenefuran-2(5H)-one [FL-no: 10.042] was 
negative in the 24 + 0 hour protocol, but equivocal results were obtained with 3,4-dimethyl-5-
pentylidenefuran-2(5H)-one [FL-no: 10.042] as well as for furan-2(5H)-one [FL-no: 10.066] in the 3 + 
21 hours protocol in the absence of the S9-mix. Furthermore, in the presence of the S9-mix these two 
substances unequivocally induced micronuclei. The Panel therefore concluded that 3,4-dimethyl-5-
pentylidenefuran-2(5H)-one [FL-no: 10.042] and furan-2(5H)-one [FL-no: 10.066] raise concern with 
respect to genotoxicity in vitro and accordingly, these two substances [FL-no: 10.042 and 10.066] and 
the seven substances  [FL-no: 10.034, 10.036, 10.043, 10.046, 10.054, 10.057 and 10.060] of subgroup 
4.1 for which these two substance were representatives cannot be evaluated using the Procedure until 
additional  in vivo  genotoxicity data will become available. According to the recommendations of 
EFSA Scientific Committee (EFSA, 2011) a combined micronucleus and Comet assay should be 
considered. The Comet assay should be performed at least in the liver. Flavouring Group Evaluation 217Rev1 
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CURRENT SAFETY EVALUATION STATUS APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH)  
Table 3:   Summary of Safety Evaluation of the JECFA substances in the present group (JECFA, 1998; JECFA, 2004) 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 1)  
US MSDI 
(µg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on 
the named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
10.043 
 
2,7-Dimethylocta-5(trans),7-dieno-1,4-
lactone 
 
0.0012 
 
Class I 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.054 
 
Non-2-eno-1,4-lactone 
 
0.012 
 
Class I 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.066 
 
Furan-2(5H)-one 
 
0.61 
 
Class I 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.034 
1163 
5,6-Dihydro-3,6-dimethylbenzofuran-
2(4H)-one 
 
1.5 
9 
Class III 
A3: Intake below threshold 
4)  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.036 
1162 
5,6,7,7a-Tetrahydro-3,6-
dimethylbenzofuran-2(4H)-one 
 
3.5 
9 
Class III 
A3: Intake below threshold 
4)  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
13.012 
1172 
6-Methylcoumarin 
 
250 
96 
Class III 
B3: Intake above threshold 
Data must be available 
5) 
Adequate data are available to 
reach the conclusion "No safety 
concern at the estimated level of 
intake based on the MSDI 
approach.". 
10.023 
222 
5-Ethyl-3-hydroxy-4-methylfuran-
2(5H)-one 
 
11 
6.1 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4)  Evaluated in FGE.217Rev1,  
genotoxicity concern ruled out. 
Evaluated by JECFA before 
2000. 
.10.030 
243 
3-Hydroxy-4,5-dimethylfuran-2(5H)-
one 
 
1.8 
0.1 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4)  Evaluated in FGE.217Rev1,  
genotoxicity concern ruled out. 
Evaluated by JECFA before 
2000. 
10.042 
 
3,4-Dimethyl-5-pentylidenefuran-2(5H)-
one 
 
0.12 
 
Class III 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.060 
 
2-Decen-1,4-lactone 
 
0.037 
 
Class III 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
O
O
O
O
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Table 3:   Summary of Safety Evaluation of the JECFA substances in the present group (JECFA, 1998; JECFA, 2004) 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 1)  
US MSDI 
(µg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on 
the named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
10.046 
 
Hex-2-eno-1,4-lactone 
 
0.0024 
 
 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
10.057 
 
3a,4,5,7a-Tetrahydro-3,6-
dimethylbenzofuran-2(3H)-one   
0.012 
 
 
No evaluation 
Not evaluated by JECFA  Evaluated in FGE.217Rev1, 
additional genotoxicity data 
required. 
1)  EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2)  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3)  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4)  No safety concern based on intake calculated by the MSDI approach of the named compound. 
5)  Data must be available on the substance or closely related substances to perform a safety evaluation. 
 
   
O
O
O
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QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 10 LACTONES FROM SUBGROUP 4.1 
Table 4:   QSAR Predictions on Mutagenicity in Five Models for 10 Lactones from Subgroup 4.1 and two precursors 
FL-no 
JECFA-no 
Sub- 
group 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
ISS Local 
Model 
Ames Test 
TA100 
 
MultiCASE  
Ames test 
  
MultiCASE 
Mouse 
lymphoma 
test 
MultiCASE 
Chromosoma
l aberration 
test in CHO 
MultiCASE 
Chromosoma
l aberration 
test in CHL 
10.054 
 
4.1  Non-2-eno-1,4-lactone 
 
4188 
- 
21963-26-8 
OD  NEG  OD  EQU  OD 
10.060 
 
4.1  2-Decen-1,4-lactone 
 
- 
- 
2518-53-8 
OD  NEG  OD  EQU  OD 
10.066 
 
4.1  Furan-2(5H)-one 
 
4138 
- 
 
OD  NEG  POS  EQU  EQU 
10.034 
1163 
4.1  5,6-Dihydro-3,6-dimethylbenzofuran-
2(4H)-one 
 
3755 
- 
80417-97-6 
OD  NEG  OD  OD  OD 
10.036 
1162 
4.1  5,6,7,7a-Tetrahydro-3,6-
dimethylbenzofuran-2(4H)-one 
 
3764 
- 
13341-72-5 
OD  NEG  OD  OD  OD 
13.012 
1172 
4.1  6-Methylcoumarin 
 
2699 
579 
92-48-8 
OD  POS  OD  OD  OD 
10.023 
222 
4.1  5-Ethyl-3-hydroxy-4-methylfuran-2(5H)-
one 
 
3153 
2300 
698-10-2 
OD  NEG  NEG  NEG  NEG 
10.030 
243 
4.1  3-Hydroxy-4,5-dimethylfuran-2(5H)-one 
 
3634 
11834 
28664-35-9 
OD  NEG  NEG  NEG  NEG 
10.042 
 
4.1  3,4-Dimethyl-5-pentylidenefuran-2(5H)-
one 
 
4050 
11873 
774-64-1 
OD  OD  OD  OD  OD 
O
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O
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Table 4:   QSAR Predictions on Mutagenicity in Five Models for 10 Lactones from Subgroup 4.1 and two precursors 
FL-no 
JECFA-no 
Sub- 
group 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
ISS Local 
Model 
Ames Test 
TA100 
 
MultiCASE  
Ames test 
  
MultiCASE 
Mouse 
lymphoma 
test 
MultiCASE 
Chromosoma
l aberration 
test in CHO 
MultiCASE 
Chromosoma
l aberration 
test in CHL 
10.046 
 
4.1  Hex-2-eno-1,4-lactone 
 
- 
- 
2407-43-4 
OD  NEG  OD  POS  OD 
Not in 
Register 
2.6  3-methyl-6-(1-carboxyethyl)-2-
cyclohexen-1-one   
 
- 
- 
- 
OD  NEG  OD  NEG  EQU 
Not in 
Register 
1.2.4  2,7-dimethyl-4-oxo-oct-5,7-dienoic acid 
 
  NYA  NYA  NYA  NYA  NYA 
Column 2: Structure group 1.1.3: Aliphatic acyclic alpha,beta--unsaturated 3-alkylated aldehydes.  
Column 6: Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD: out of domain; NYA: not yet assessed). 
Column 7: MultiCase Ames test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal; NYA: not yet assessed). 
Column 8: MultiCase Mouse lymphoma test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal; NYA: not yet assessed). 
Column 9: MultiCase Chromosomal aberration in CHO (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal; NYA: not yet assessed). 
Column 10: MultiCase Chromosomal aberration in CHL (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal; NYA: not yet assessed). 
OD: out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, biological etc. 
O
O
O
O
OH
OH
O
OFlavouring Group Evaluation 217Rev1 
 
EFSA Journal 2013;11(7):3304  20 
CARCINOGENICITY STUDIES 
Table 5:   Carcinogenicity Studies 
Chemical Name  
[FL-no]  
Species; Sex 
No./Group 
Route   Dose levels  Duration  Results  Reference  Comments 
6-Methylcoumarin  
[13.012] 
Rat; Male, Female 
25/sex/group 
Diet  0,  25, 50, 175, 250, 
375 or 750 mg/kg 
bw/day 
2 years  Males and females: No 
increases in tumour 
incidences  
(Hagan et al., 
1967) 
The study is not in accordance with OECD Guidelines or 
current standards. Under the condition of the study the 
negative result is considered valid. The NOAEL was 250 
mg/kg bw/day based on growth depression and slight liver 
changes, particularly in males at the higher dose levels. 
The study is reported together with the results of studies of 
many more flavouring substances with and without related 
structures. Therefore, no detailed description of the 
findings is given. 
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GENOTOXICITY (IN VITRO) 
Table 6:   Genotoxicity (in vitro) 
Chemical Name  
[FL-no]  
Test System  Test Object   Concentration  Result   Reference   Comments 
d 
6-methylcoumarin  
[13.012] 
 
Reverse mutation  S. typhimurium TA100  5 concentrations up to 
cytotoxicity,  or max 3600 
µg/plate 
Marginally positive
c  (Wild et al., 1983) 
 
Valid, however the results are considered 
equivocal (+ S9: dose-response showed positive 
trend, but was never above twice control 
frequency; - S9: negative). 
Reverse mutation  S. typhimurium TA98, TA1535, 
TA1537, and TA1538 
5 concentrations up to 
cytotoxicity,  or max. 3600 
µg/plate 
Negative
a  (Wild et al., 1983) 
 
Valid.  
Reverse mutation  S. typhimurium TA98, TA100, 
TA1535, and TA1537 
33–3333 µg/plate  Negative
a,b  (Haworth et al., 
1983) 
 
Valid. 
Reverse mutation  S. typhimurium TA98, TA100, 
TA1535, TA1537 and TA1538 
1–5000 µg/plate  Negative
a  (Brusick, 1982) 
 
Valid. Unpublished GLP study carried out 
according to current OECD guideline; 
result is considered as valid. 
Forward mutation   Mouse lymphoma L5178Y Tk 
+/-cells 
6.25–100 µg/ml  Negative
c  (Cifone, 1982) 
 
Valid. Unpublished GLP study carried out 
according to current OECD guideline; 
result is considered as valid. 
Forward mutation   Mouse lymphoma L5178Y Tk 
+/-cells 
15.6–250 µg/ml  Negative  (Cifone, 1982) 
 
Valid. Unpublished GLP study carried out 
According to current OECD guideline; 
result is considered as valid.  
a: With and without metabolic activation. 
b: Pre-incubation method. 
c: With metabolic activation. 
d: Validity of genotoxicity studies: 
  Valid. 
  Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
  Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
  Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). Flavouring Group Evaluation 217Rev1 
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GENOTOXICITY (IN VIVO) 
Table 7:   Genotoxicity (in vivo) 
Chemical Name 
[FL-no]  
Test System  Test Object   Route  Dose  Result   Reference   Comments 
a 
6-Methylcoumarin 
[13.012] 
 
Sex-linked recessive 
lethal mutation 
Drosophila 
melanogaster 
Feed  10 mmol/l (1602 µg/ml)  Negative  (Wild et al., 1983)  Limited validity (limited reporting, 
study system considered of limited 
relevance). 
  Micronucleus 
formation 
Mouse peripheral blood 
cells 
Oral 
(Gavage) 
200 and 400 mg/kg for 90 
days 
Equivocal 
(M)
 
Negative (F) 
(Witt et al., 2000)  Limited validity (not a standard 
protocol; exposure for 90 days; no 
information on cytotoxicity; no 
positive controls). 
  Micronucleus 
formation 
Mouse bone-marrow 
cells 
i.p.  160, 240, and 320 mg/kg  Negative  (Wild et al., 1983)  Limited validity (only analysis at one 
time point; no PCE/NCE ratio 
reported). 
a: Validity of genotoxicity studies: 
  Valid. 
  Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
  Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
  Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). Flavouring Group Evaluation 217Rev1 
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NEW GENOTOXICITY (IN VITRO)  
Table 8:   Summary of Additionally Genotoxicity Data [FL-no: 10.023, 10.042 and 10.066] of subgroup 4.1 
Chemical Name 
[FL-no:] 
Test System in 
vitro  
Test Object   Concentrations of 
Substance and Test 
Conditions  
Result   Reference   Comments  
5-ethyl-3-hydroxy-4-
methylfuran-2(5H)-one 
[10.023] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
1.6, 8, 40, 200, 1000 and 
5000 μg/plate [1,2] 
Negative   (Bowen, 2011a)  Valid study in accordance with OECD Guideline 471 
(OECD, 1997) and in compliance with GLP. Evidence 
of toxicity was observed in strain TA1537 in the 
presence of S9-mix at 5000 μg/plate and in strain 
TA102 in the presence of S9-mix at 200 μg/plate and 
above. Further evidence of toxicity in the form of a 
reduction in revertant numbers was observed in strain 
TA1535 in the presence of S9-mix and in strain TA102 
in the absence of S9-mix at 5000 µg/plate. 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
156.3, 312.5, 625, 1250, 
2500 and 5000 μg/plate 
[2,3] 
Negative  Evidence of toxicity was observed in the presence of 
S9-mix in strains TA1537 and TA102 at 2500 μg/plate 
and above. Further evidence of toxicity in the form of a 
reduction in revertant numbers was observed in strains 
TA98 in the presence of S9-mix at 5000 µg/plate and in 
strains TA98 and TA 102 in the absence of S9-mix at 
5000 and 2500 µg/plate, resp.   
156.3, 312.5, 625, 1250, 
2500 and 5000 μg/plate 
[4,5] 
Negative 
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes  
1000, 1200 and 1422 
μg/ml (equivalent to 10 
mM) [1,6] 
Negative  (Lloyd, 2011)   Valid study in accordance with draft OECD Guideline 
487 (OECD, 2010) and in compliance with GLP. A top 
concentration of 10 mM was employed or an acceptable 
level of  cytotoxicity was achieved at the top 
concentration used in the continuous treatment 
schedule. 
500, 750 and 900 μg/ml 
[3,7] 
Negative 
3,4-Dimethyl-5-
pentylidenefuran-2(5H)-one 
[10.042] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
and TA102 
0.32, 1.6, 8, 40, 200, 1000 
and 5000 μg/plate [1,2] 
Negative  (Bowen, 2011b)   Valid study in accordance with OECD Guideline 471 
(OECD, 1997) and in compliance with GLP. Evidence 
of toxicity was observed in all strains in the absence and 
presence of S9 at 200 μg/plate and above. 
S. typhimurium TA98, 
TA102, TA1535 
78.13 - 5000 μg/plate [2,3] 
78.13 - 5000 μg/plate [4,5]  
Negative  Evidence of toxicity was observed in 
strain TA102 in the presence of S9 at 1250 μg/plate and 
above, and for all other treatment conditions at either 
312.5 or 625 μg/plate and above. 
S. typhimurium  TA100  19.53 - 1250 μg/plate [2,3] 
78.13 - 5000 μg/plate [4,5]  
S. typhimurium TA1537  9.76 - 1250 μg/plate [2,3] 
78.13 - 5000 μg/plate [4,5]  
S. typhimurium TA1537  19.53 - 1250 μg/plate [4,5]  Negative  Evidence of toxicity was observed at 156.3 μg/plate and 
above.  Flavouring Group Evaluation 217Rev1 
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Table 8:   Summary of Additionally Genotoxicity Data [FL-no: 10.023, 10.042 and 10.066] of subgroup 4.1 
Chemical Name 
[FL-no:] 
Test System in 
vitro  
Test Object   Concentrations of 
Substance and Test 
Conditions  
Result   Reference   Comments  
In vitro 
Micronucleus 
induction 
Human peripheral blood 
lymphocytes 
40, 60, 70 and 90 μg/ml 
[3,6] 
Equivocal  (Whitwell, 2012a) 
Whitwell (2012a) 
Valid study in accordance with OECD Guideline 487 
(OECD, 2010)  and in compliance with GLP. 
60, 90, 110, and 140 μg/ml 
[5,6] 
Positive 
10, 13, and 15 μg/ml [3,7]  Negative 
Furan-2(5H)-one [10.066]  Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
0.32, 1.6, 8, 40, 200, 1000, 
and 5000 μg/plate [1,2] 
Negative  (Bowen, 2011c)   Valid study in accordance with OECD Guideline 471 
(OECD, 1997) and in compliance with GLP. Evidence 
of toxicity was observed in all treatment conditions in 
the absence and presence of S9 at 5000 μg/plate, with 
the exception of TA100 in the presence of S9 and strain 
TA1535 in the absence of S9.  
156.3, 312.5, 625, 1250, 
2500 and 5000 μg/plate 
[2,3]  
156.3, 312.5, 625, 1250, 
2500 and 5000 μg/plate 
[4,5] 
Negative  Evidence of toxicity was observed in all treatment 
conditions in the absence and presence of S9 at 2500 
and/or 5000 μg/plate.  
In vitro 
Micronucleus 
induction 
Human peripheral blood 
lymphocytes 
200, 350, 425, 450 and 
475 μg/ml [3,6] 
Equivocal  (Whitwell, 2012b)   Valid study in accordance with OECD Guideline 487 
(OECD, 2010)  and in compliance with GLP. 
100, 250, 425, 450 and 
475 μg/ml [5,6] 
Positive 
10, 50, 60, 67.5 and 72.5 
μg/ml [3,7] 
Equivocal 
[1] With and without S9 metabolic activation. 
[2] Plate incorporation method. 
[3] Without S9 metabolic activation. 
[4] Pre-incubation method. 
[5] With S9 metabolic activation. 
[6] 3-hour incubation with 21-hour recovery period. 
[7] 24-hour incubation with no recovery period. 
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ABBREVIATIONS   
BW    Body Weight 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO    Chinese Hamster Ovary (cells) 
CHL    Chinese Hamster Lung (cells) 
CoE    Council of Europe 
EC    European Commission 
EFSA    The European Food Safety Authority 
EU    European Union 
FAO    Food and Agriculture Organization 
FGE    Flavouring Group Evaluation  
FLAVIS (FL)  Flavour Information System (database) 
GLP    Good Laboratory Practice 
ID    Identity 
IR    Infrared spectroscopy 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
MNBN   MicroNucleated BiNucleate cells 
MS    Masse Spectra 
NMR    Nuclear Magnetic Resonance 
No    Number 
NAOEL  No Observed Adverse Effect Level 
OECD    Organisation for Economic Co-operation and Development 
PCE    PolyChromatic Erythrocytes 
(Q)SAR  (Quantitative) Structure Activity Relationship 
RI    Replication Index 
SCF    Scientific Committee on Food 
WHO    World Health Organisation 